Medically reviewed by Sanja Jelic, MD Key Takeaways CPAP therapy creates pressure that helps keep your airway open while you ...

ResMed is betting big on artificial intelligence (AI) to boost CPAP adherence. At the recent J.P. Morgan Healthcare Conference, CEO Mick Farrell said the company’s first AI-enabled medical device, Sma ...

Beginning CPAP therapy may come with many questions; we are here to answer them. CPAP therapy can provide many benefits, including improved sleep, alertness, heart health, mental health, and more.

Supplemental Clearance Opens Institutional Markets and Expands Patient Population Beyond Traditional CPAP Therapy BLACKSHEAR, GA - January 15, 2026 (NEWMEDIAWIRE) - REMSleep Holdings, Inc. (OTCQB: ...

SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint ...

Please provide your email address to receive an email when new articles are posted on . Researchers pooled together randomized controlled trials and non-randomized controlled studies reporting on CPAP ...

Air Voel is shining a spotlight on the latest generation of sleep apnea therapy with the AirSense 11 CPAP machines, a ...

From leaving your phone in another room to investing in blackout curtains and white noise machines, there’s no shortage of ...

The utilization of positive airway pressure (PAP) therapy is associated with reduced rates of mortality and incidence of major adverse cardiovascular events (MACEs) in older adults with obstructive ...

People with obstructive sleep apnea may have a higher risk of developing Parkinson’s disease, but early use of continuous positive airway pressure (CPAP) therapy could help lower that risk. A ...

Positive airway pressure (PAP) therapy devices are widely used to treat many of the approximately 30 million people managing sleep apnea in the United States. CPAP (Continuous positive airway pressure ...

Tirzepatide achieved a mean apnea-hypopnea index reduction of up to 63% (about 30 fewer events per hour), meeting all primary and key secondary endpoints in two phase 3 clinical trials Tirzepatide ...